Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus LEVOCETIRIZINE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus LEVOCETIRIZINE DIHYDROCHLORIDE.
BENADRYL vs LEVOCETIRIZINE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Category C
Category A/B
Antihistamine
Antihistamine